| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 10, 2021 | Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update | |
| Aug 3, 2021 | Cumberland Pharmaceuticals To Announce Second Quarter 2021 Financial Results | |
| Jul 26, 2021 | Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020 | |
| Jun 21, 2021 | Vibativ® Effectively Helps Treat Secondary Bacterial Infections In COVID-19 Patients | |
| May 11, 2021 | Cumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update | |
| May 4, 2021 | Cumberland Pharmaceuticals To Announce First Quarter 2021 Financial Results | |
| Mar 9, 2021 | Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020 | |
| Mar 2, 2021 | Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results | |
| Nov 10, 2020 | Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update | |
| Nov 3, 2020 | Cumberland Pharmaceuticals To Announce Third Quarter 2020 Financial Results | |
| Aug 18, 2020 | Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use | |
| Oct 28, 2007 | IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings | Bioheart’s IPO-related chest pains continue — The week of Oct. 22 has come and gone, and there’s no sign of the scheduled — and already battered — IPO of Bioheart, the Florida company that hopes to treat damaged hearts with patients’ own mu... |
| Aug 15, 2007 | Amgen grabs the axe, chops up to 2,600 jobs | (UPDATED: See below.)
The biotech colossus Amgen, stung by safety and regulatory issues that hit hard at sales of its core anemia drugs, announced today that it will cut its headcount between 12 percent and 14 percent, ratchet back on new p... |
| Jul 26, 2007 | Cumberland Pharma hopes for $115M in IPO | Cumberland Pharmaceuticals, a Nashville, Tenn., specialty pharmaceutical company with a hodgepodge of acquired products, priced its IPO and now hopes to raise as much as $115 million. The company plans to offer 6.25 million shares, plus a p... |